<DOC>
	<DOCNO>NCT00143416</DOCNO>
	<brief_summary>Primary objective : To investigate efficacy safety Pegvisomant Japanese patient acromegaly .</brief_summary>
	<brief_title>Long Term Study With B2036-PEG</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<criteria>Patients acromegaly receive least one dose B2036PEG preceding study ( A6291009 ) . Switching therapeutic method acromegaly</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>